N/A
Manufactured by Actavis Pharma, Inc.
24,476 FDA adverse event reports analyzed
Last updated: 2026-04-14
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Actavis Pharma, Inc.. The most commonly reported adverse reactions for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE include HEADACHE, NAUSEA, DRUG INEFFECTIVE, FATIGUE, PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE.
Out of 10,441 classified reports for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 24,476 FDA FAERS reports that mention BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include HEADACHE, NAUSEA, DRUG INEFFECTIVE, FATIGUE, PAIN, MIGRAINE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Actavis Pharma, Inc. in connection with BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE. Always verify the specific product and NDC with your pharmacist.